1. Meta-analysis of pooled RR comparing cancer risk of the high
with low BW
We compared the highest dose of BW with the low group of each study and
subsequently combined them to calculate the pooled RR. Our analysis
found that the risk of six cancers we selected has a significant
relationship with BW. Five of them showed that higher BW was the risk
factor. (Ovarian cancer: pooled RR=1.21, 95%CI=1.01-1.44,
I2=11%, p=0.34; breast cancer: pooled RR=1.12,
95%CI=1.08-1.16, I2=48%, p<0.01;
colorectal cancer: pooled RR=1.20, 95%CI=1.01-1.43,
I2=0%, p=0.87; prostate cancer: pooled RR=1.27,
95%CI=1.01-1.61, I2=0%, p=0.93; testicular cancer:
pooled RR=1.21, 95%CI=1.03-1.43, I2=0%, p=0.84)
However, higher BW were likely to be the protective factor of
endometrial cancer (pooled RR=0.78, 95%CI=0.78-0.93,
I2=0%, p=0.63). (Figure S2- S7)